Vigil Neuroscience (NASDAQ:VIGL) Stock Rating Reaffirmed by JMP Securities

JMP Securities restated their market outperform rating on shares of Vigil Neuroscience (NASDAQ:VIGL) in a research note released on Thursday, Benzinga reports. They currently have a $23.00 price target on the stock.

Separately, HC Wainwright reissued a buy rating and issued a $24.00 target price on shares of Vigil Neuroscience in a report on Wednesday, March 27th.

Vigil Neuroscience Stock Down 5.8 %

Shares of NASDAQ VIGL opened at $2.75 on Thursday. The business has a 50-day moving average of $3.17 and a two-hundred day moving average of $4.02. Vigil Neuroscience has a 1 year low of $2.53 and a 1 year high of $11.11.

Vigil Neuroscience (NASDAQ:VIGL) last announced its quarterly earnings results on Tuesday, March 26th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.01). Equities research analysts anticipate that Vigil Neuroscience will post -2.56 EPS for the current fiscal year.

Institutional Trading of Vigil Neuroscience

Institutional investors and hedge funds have recently made changes to their positions in the company. Strs Ohio purchased a new stake in shares of Vigil Neuroscience in the 4th quarter valued at about $27,000. Royal Bank of Canada acquired a new position in Vigil Neuroscience in the 2nd quarter valued at about $33,000. California State Teachers Retirement System acquired a new position in Vigil Neuroscience in the 2nd quarter valued at about $50,000. Wells Fargo & Company MN increased its position in Vigil Neuroscience by 6,988.4% in the 2nd quarter. Wells Fargo & Company MN now owns 6,096 shares of the company’s stock valued at $57,000 after acquiring an additional 6,010 shares during the period. Finally, MetLife Investment Management LLC acquired a new position in Vigil Neuroscience in the 2nd quarter valued at about $86,000. 83.64% of the stock is owned by hedge funds and other institutional investors.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.